With current Gilead Sciences (Nasdaq: GILD) chief executive John Milligan standing down at the end of the year, the announcement on his successor is one of the most eagerly-awaited in biopharma at present.
RBC Capital Markets analyst Brian Abrahams has made three major observations in a report about the appointment that was published on Tuesday.
Mr Abrahams suggests that a chief executive with a history of success in business development would be very well-received, given Gilead’s cash pile to spend on in-licensing deals and acquisitions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze